Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France.
Phase of Trial: Phase IV
Latest Information Update: 01 Oct 2017
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DIAPAZON
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 01 Oct 2017 Results published in the Diabetes Therapy
- 23 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Aug 2013 Planned end date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.